<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00595361</url>
  </required_header>
  <id_info>
    <org_study_id>2007-P-002199</org_study_id>
    <nct_id>NCT00595361</nct_id>
  </id_info>
  <brief_title>How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment</brief_title>
  <acronym>SECS</acronym>
  <official_title>The Effect of Beta-2 Adrenergic Polymorphisms on the Bronchoprotective Effects of Regular Salmeterol Treatment in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to find out how well a long-acting beta agonist like salmeterol
      works in people with different forms of the same gene. Our hypothesis is that asthmatics with
      the Arg/Arg genotype will have loss of bronchoprotection against exercise-induced asthma with
      regular salmeterol treatment, as compared to asthmatics with the Gly/Gly genotype.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In many patients with asthma, exercise-induced bronchoconstriction is a common and oftentimes
      limiting characteristic. Inhaled β2-adrenoreceptor agonists like albuterol are the most
      effective treatments available for the relief of acute asthma symptoms. However, there is
      evidence that regular use may lead to adverse effects in some patients. Previous studies have
      shown that polymorphisms of the β2-adrenergic receptor can influence airway responses to
      regular inhaled beta-agonist treatment.

      Pharmacogenetics is the study of how genetic differences influence the variability in
      patients' responses to therapy, both therapeutic and adverse. Genetic susceptibility and
      environmental factors both play major roles in the etiology of asthma. The strong familial
      clustering of asthma has lead to a surge of research into the genetic predisposition of
      asthma. The aim of the present study is to utilize a double-blinded prospective cohort study
      to investigate whether genotype-specific effects occur when assessing the duration of
      protection conferred against exercise-induced bronchoconstriction by regular salmeterol
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the Maximum Percent Fall in FEV1 After Exercise Challenge at the End of the 2-week Treatment Period Between Arg/Arg and Gly/Gly Patients</measure>
    <time_frame>2 weeks after exercise challenge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Maximum Percent Fall in FEV1 From Pre-salmeterol Baseline to the End of the 2-week Treatment Period Between Arg/Arg and Gly/Gly Patients</measure>
    <time_frame>2 weeks from pre-salmeterol baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Maximum Percent Fall in FEV1 After 1st Dose of Salmeterol to the End of the 2-week Treatment Period Between Arg/Arg and Gly/Gly Subjects</measure>
    <time_frame>2 weeks after 1st dose of Salmeterol</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Arg/Arg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arg/Arg subjects on 2 week salmeterol treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gly/Gly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gly/Gly subjects on 2 week salmeterol treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol</intervention_name>
    <description>salmeterol 50 micrograms twice daily for 2 weeks</description>
    <arm_group_label>Arg/Arg</arm_group_label>
    <arm_group_label>Gly/Gly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both male and female

          -  18 to 50 years of age

          -  Resting FEV1 ≥ 65% of predicted normal

          -  Exercise-induced bronchoconstriction defined as a decrease in FEV1 of ≥ 20% following
             a standardized exercise challenge when compared to pre-exercise baseline FEV1 value
             measured 5 minutes before exercise

          -  Must be Arg/Arg or Gly/Gly genotype

        Exclusion Criteria:

          -  Long-acting beta agonist use within 12 weeks of the first exercise challenge

          -  Smoking within past 12 months

          -  Greater than 10-pack years smoking history

          -  Unresolved signs and/or symptoms of an upper respiratory tract infection within 4
             weeks of first exercise challenge

          -  Asthma exacerbation within 4 weeks of first exercise challenge requiring change in
             type, dose or frequency of medications and/or an unscheduled visit to an health care
             provider, including emergency room or hospital

          -  Subject has exercised or performed strenuous activity within 72 hours of the first
             exercise challenge

          -  Subject has been exposed to cold air sufficient to provoke symptoms of bronchospasm
             within 2 hours of exercise challenge

          -  In addition to asthma, the subject has an active, acute or chronic pulmonary disorder
             documented by history, physical examination, or chest x-ray

          -  Subject has evidence of ischemic, valvular, hypertrophic, familial or other forms of
             heart disease that would put the subject at risk during exercise testing or that would
             interfere with the ability to achieve protocol-specified heart rates during exercise
             testing

          -  Subject has used systemic corticosteroids within 1 month of first exercise challenge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot Israel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asthma Research Center, Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, Cooper DM, Fahy JV, Fish JE, Ford JG, Kraft M, Kunselman S, Lazarus SC, Lemanske RF, Martin RJ, McLean DE, Peters SP, Silverman EK, Sorkness CA, Szefler SJ, Weiss ST, Yandava CN. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000 Jul;162(1):75-80.</citation>
    <PMID>10903223</PMID>
  </results_reference>
  <results_reference>
    <citation>Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J, Kraft M, Kunselman SJ, Lazarus SC, Lemanske RF Jr, Liggett SB, Martin RJ, Mitra N, Peters SP, Silverman E, Sorkness CA, Szefler SJ, Wechsler ME, Weiss ST, Drazen JM; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004 Oct 23-29;364(9444):1505-12.</citation>
    <PMID>15500895</PMID>
  </results_reference>
  <results_reference>
    <citation>Wechsler ME, Lehman E, Lazarus SC, Lemanske RF Jr, Boushey HA, Deykin A, Fahy JV, Sorkness CA, Chinchilli VM, Craig TJ, DiMango E, Kraft M, Leone F, Martin RJ, Peters SP, Szefler SJ, Liu W, Israel E; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006 Mar 1;173(5):519-26. Epub 2005 Dec 1.</citation>
    <PMID>16322642</PMID>
  </results_reference>
  <results_reference>
    <citation>Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med. 1994 May;88(5):363-8.</citation>
    <PMID>7913549</PMID>
  </results_reference>
  <results_reference>
    <citation>Yates DH, Worsdell M, Barnes PJ. Effect of regular salmeterol treatment on albuterol-induced bronchoprotection in mild asthma. Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):988-91.</citation>
    <PMID>9310023</PMID>
  </results_reference>
  <results_reference>
    <citation>Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER Jr. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med. 1998 Jul 16;339(3):141-6.</citation>
    <PMID>9664089</PMID>
  </results_reference>
  <results_reference>
    <citation>Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax. 2006 Nov;61(11):940-4. Epub 2006 Jun 13.</citation>
    <PMID>16772309</PMID>
  </results_reference>
  <results_reference>
    <citation>Israel E. Genetics and the variability of treatment response in asthma. J Allergy Clin Immunol. 2005 Apr;115(4 Suppl):S532-8. Review.</citation>
    <PMID>15806036</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2008</study_first_submitted>
  <study_first_submitted_qc>January 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <results_first_submitted>July 16, 2014</results_first_submitted>
  <results_first_submitted_qc>July 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2014</results_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Elliot Israel, MD</investigator_full_name>
    <investigator_title>Director, Asthma Research Center</investigator_title>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>exercise induced asthma</keyword>
  <keyword>exercise induced bronchoconstriction</keyword>
  <keyword>long acting beta agonist</keyword>
  <keyword>salmeterol</keyword>
  <keyword>exercise challenge</keyword>
  <keyword>bronchoprotection</keyword>
  <keyword>beta 2 adrenergic receptor polymorphisms</keyword>
  <keyword>pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arg/Arg</title>
          <description>Arg/Arg subjects on 2 week salmeterol treatment
salmeterol: salmeterol 50 micrograms twice daily for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Gly/Gly</title>
          <description>Gly/Gly subjects on 2 week salmeterol treatment
salmeterol: salmeterol 50 micrograms twice daily for 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arg/Arg</title>
          <description>Arg/Arg subjects on 2 week salmeterol treatment
salmeterol: salmeterol 50 micrograms twice daily for 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Gly/Gly</title>
          <description>Gly/Gly subjects on 2 week salmeterol treatment
salmeterol: salmeterol 50 micrograms twice daily for 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.8" spread="2.4"/>
                    <measurement group_id="B2" value="27.2" spread="1.4"/>
                    <measurement group_id="B3" value="26.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of the Maximum Percent Fall in FEV1 After Exercise Challenge at the End of the 2-week Treatment Period Between Arg/Arg and Gly/Gly Patients</title>
        <time_frame>2 weeks after exercise challenge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arg/Arg</title>
            <description>Arg/Arg subjects on 2 week salmeterol treatment
salmeterol: salmeterol 50 micrograms twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Gly/Gly</title>
            <description>Gly/Gly subjects on 2 week salmeterol treatment
salmeterol: salmeterol 50 micrograms twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the Maximum Percent Fall in FEV1 After Exercise Challenge at the End of the 2-week Treatment Period Between Arg/Arg and Gly/Gly Patients</title>
          <units>% fall FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="4.5"/>
                    <measurement group_id="O2" value="16.5" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of the Maximum Percent Fall in FEV1 From Pre-salmeterol Baseline to the End of the 2-week Treatment Period Between Arg/Arg and Gly/Gly Patients</title>
        <time_frame>2 weeks from pre-salmeterol baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arg/Arg</title>
            <description>Arg/Arg subjects on 2 week salmeterol treatment
salmeterol: salmeterol 50 micrograms twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Gly/Gly</title>
            <description>Gly/Gly subjects on 2 week salmeterol treatment
salmeterol: salmeterol 50 micrograms twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the Maximum Percent Fall in FEV1 From Pre-salmeterol Baseline to the End of the 2-week Treatment Period Between Arg/Arg and Gly/Gly Patients</title>
          <units>% fall FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="19.9"/>
                    <measurement group_id="O2" value="4.3" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of the Maximum Percent Fall in FEV1 After 1st Dose of Salmeterol to the End of the 2-week Treatment Period Between Arg/Arg and Gly/Gly Subjects</title>
        <time_frame>2 weeks after 1st dose of Salmeterol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arg/Arg</title>
            <description>Arg/Arg subjects on 2 week salmeterol treatment
salmeterol: salmeterol 50 micrograms twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Gly/Gly</title>
            <description>Gly/Gly subjects on 2 week salmeterol treatment
salmeterol: salmeterol 50 micrograms twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the Maximum Percent Fall in FEV1 After 1st Dose of Salmeterol to the End of the 2-week Treatment Period Between Arg/Arg and Gly/Gly Subjects</title>
          <units>% fall FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.6" spread="17.1"/>
                    <measurement group_id="O2" value="-16.5" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arg/Arg</title>
          <description>Arg/Arg subjects on 2 week salmeterol treatment
salmeterol: salmeterol 50 micrograms twice daily for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Gly/Gly</title>
          <description>Gly/Gly subjects on 2 week salmeterol treatment
salmeterol: salmeterol 50 micrograms twice daily for 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elliot Israel, MD</name_or_title>
      <organization>Brigham and Women's Hopsital</organization>
      <phone>617-732-8110</phone>
      <email>eisrael@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

